SRZN surrozen.com Net earnings per share growth forecast for next year

The forward-looking EPS growth vector for next year reflects expert expectations, while 69.60 shows the current value of the metric. Surrozen, Inc. (SRZN) develops tissue regeneration therapies via Wnt signaling, funding research into intestinal and liver diseases. The business model minimizes costs by outsourcing trials to external CROs. Unique patents for specific antibodies provide the company's technological edge.

Surrozen Corp (SRZN): Expected earnings per share trend next year from 07/04/2022 to 11/15/2026

Surrozen (SRZN) - metric breakdowns and financial figures

- stock quotes and analyst forecast:

Stock Quotes Surrozen Inc.|SRZN - Analyst Consensus Forecast

- market capitalization data:

Market Value Surrozen Corp|SRZN - Value Adjusted for Debt and Cash

- company book value details:

Net Assets per Single Share Surrozen|SRZN - Accounting Value of Company|Market Value to Book Value Ratio surrozen.com|SRZN - Company Assets

- company total debt and liquidity indicators:

- net income and valuation ratios data:

SRZN - Net Financial Result|Expected Profit Surrozen, Inc.|SRZN - Price to Earnings Multiple|Forward P/E Multiple Surrozen Inc|SRZN - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Surrozen Inc.|SRZN - Operating income before deduction of amortization|Earnings per share for the last twelve months Surrozen|SRZN - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months surrozen.com|SRZN - Earnings per share increase in current year|Expected earnings per share growth for next year Surrozen, Inc.

- sales and revenue indicators:

SRZN - Company Annual Revenue|Company Projected Revenue Surrozen|SRZN - Market Cap to Revenue Ratio|Price-to-Projected Revenue Ratio Surrozen Inc.|SRZN - Annual Revenue Growth (Last Twelve Months)

Fundamental company analysis:SRZN, Surrozen

This indicator captures the market consensus regarding the growth rate of earnings per share, reflecting aggregate expert expectations for future returns. Calculated values are based on current forecasts; therefore, the current projected EPS growth for the next period serves as a gauge of market confidence in the company's success. For Surrozen, Inc. (SRZN), this trend is driven exclusively by the results of stem cell clinical trials, ignoring external macroeconomic factors.

Competing companies

MESO (Mesoblast Ltd) - Earnings growth forecast for next year|lineagecell.com (LCTX) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year CCEL (Cryo-Cell International)|Net earnings per share growth forecast for next year FBLG (FibroBiologics Inc.)|Earnings growth forecast for next year LGVN (Longeveron Inc)|Expected earnings per share trend next year BRTX|CELZ: Expected earnings per share growth for next year